-

06:16:52 AM

SYN Stock News

SYN - Synthetic Biologics Inc

05/16/22 8:00 AM

AMEX : SYN

earnings

Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results

-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- -

RHEA-AI

neutral

05/10/22 8:00 AM

AMEX : SYN

clinical trial

Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of

RHEA-AI

neutral

05/09/22 8:00 AM

AMEX : SYN

conferencesearnings

Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, May 16, 2022, at

RHEA-AI

neutral

05/05/22 8:00 AM

AMEX : SYN

management

Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified

RHEA-AI

neutral

05/04/22 8:00 AM

AMEX : SYN

Synthetic Biologics Announces Presentation on VCN-11, a Novel Oncolytic Adenovirus Designed to Evade Neutralizing Antibodies at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

- VCN-11 incorporates a proprietary albumin binding domain in the virus shell with the potential to improve systemic delivery and extend therapeutic efficacy through a multi-dosing strategy- - Data to be featured in an oral presentation on Monday, May 16 at 5:15 p.m. ET- ROCKVILLE, Md., May 04,

RHEA-AI

neutral

03/28/22 4:05 PM

AMEX : SYN

clinical trial

Synthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients With Advanced Solid Tumors

-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and identify recommended Phase 2 dose (RP2D)- -Publication further supports the development of Synthetic Biologics’ novel oncolytic adenovirus (OV) platform- ROCKVILLE, Md., March 28, 2022 (GLOBE

RHEA-AI

neutral

03/23/22 8:00 AM

AMEX : SYN

management

Synthetic Biologics Announces Management Transitions in Support of Strategic Transformation

-Frank Tufaro, Ph.D., appointed as Chief Operating Officer of Synthetic Biologics, transitioning from Chief Operating Officer of VCN Biosciences- -Manel Cascallό, Ph.D., appointed as General Director of Synthetic Biologics’ European Subsidiary, transitioning from Chief Operating Officer of VCN

RHEA-AI

very positive

03/22/22 4:05 PM

AMEX : SYN

conferences

Synthetic Biologics to Participate in the Maxim 2022 Virtual Growth Conference

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that Company’s Management will provide a corporate update and

RHEA-AI

neutral

03/16/22 4:05 PM

AMEX : SYN

earnings

Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results

-Completed acquisition of VCN Biosciences, expanding pipeline into oncology- -VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. FDA- -As of December 31, 2021, Synthetic Biologics reports $67.3 million in cash, which is expected to provide runway through the end of 2023-

RHEA-AI

positive

03/11/22 8:00 AM

AMEX : SYN

acquisition

Synthetic Biologics Completes Acquisition of VCN Biosciences

- Expands pipeline into oncology with unique, clinical-stage oncolytic viruses optimized for intravenous administration - - Strong cash position to support multiple inflection points for VCN-01 with the start of a Phase 2 trial in combination with standard-of-care chemotherapy in patients with

RHEA-AI

very positive

SYN Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.syntheticbiologics.com
CeoSteven Shallcross
Security nameSynthetic Biologics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees10
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address9605 Medical Center Dr Ste 270
StateMaryland
CityRockville
Zip20850-6382
CountryUS
Phone17343327800

About Synthetic Biologics Inc

Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.